ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel - 101793

Spotlight
Video

ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel

VJHemOnc has 1441 videos Subscribe Here

Loading........
Description: The Phase I/II trial ZUMA-1 (NCT02348216) was pivotal for CAR T-cell development. In this interview, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, highlights how this led to FDA approval of the anti-CD19 second-generation CAR T-cell product, axicabtagene ciloleucel (axi-cel; KTE-C19), for refractory B-cell non-Hodgkin lymphoma (NHL). Dr Lin then discusses the exciting long-term follow-up data of this study. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/08/18
Added : 7 months ago